This announcement is a separate document:
荃信生物-B：(1) 2023年董事會工作報告；(2) 2023年監事會工作報告；(3) 2023年年度報告；(4) 2023年利潤分配方案；(5) 2024年董事及監事薪酬方案；(6) 委聘2024年審計師；(7) 建議授出發行H股的一般性授權；(8) 為一間附屬公司提供擔保；及2023年股東週年大會通告
QYUNS-B: (1) 2023 WORK REPORT OF THE BOARD(2) 2023 WORK REPORT OF THE BOARD OF SUPERVISORS(3) 2023 ANNUAL REPORT;(4) 2023 PROFIT DISTRIBUTION PLAN;(5) 2024 REMUNERATION SCHEME FOR DIRECTORS AND SUPERVISORS;(6) ENGAGEMENT OF THE AUDITOR FOR 2024;(7) PROPOSED G
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.